News UK biotech Astex celebrates as Novartis breast cancer drug a... Cambridge firm played key role in discovery of potential blockbuster Kisqali.
News Roche breast cancer trial success could kill Puma's rival Perjeta trial success sends rival biotech's share price crashing.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Call for Roche to lower Kadcyla price further after NICE rej... Ruling could end funding for cancer drug in England.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
